news
For Information:
Sue Pondrom
News Bureau Manaqer
(619) s54-8133
II{MEDIATE
#oB309 0-3
FULCHER, PH.D.,
A I { A R D E D T H E INTERNATIONAL
OF THE FRENCH ASSOCIATION
O F HEI.IOPHILTA
CAROTJ A.
LA JOLLA, CA Aug. 30, L990 -JoIla,
presented
was
the
International
of Hemophilia during
Association
Carol A. Fulcher,
PRIZE
Ph.D.,
of
the
the 19th fnternational
of Hernophilia
the World Federation
Prj,ze
in Washington,
RELEASE
of La
French
Congress of
D.C.,
on August
l-o.
Fulcher
and
Biology
contributions
about
therapy
is
one in
(the
VIII
hemophilia)
using
discovery,
and Research
those
who
have
for
of
the
a genetically
Study
of
Foundation.
made
significant
A pathophysiology,
in henophilia
Molecul-ar
determined
and the
genetics
disease
that
average cost
of
$60,000 per year.
coll-aborated
deveJ-op a
Department
l-0r000 male infants,
$10,000 to
Fulcher
Factor
recognizes
the
Committee
the
Clinic
HemophiJ-ia A is
affects
to
and
Scripps
to research
or therapy.
M.D. ,
at
prize
The
member in
Medicine
Experimental
Vascular
this
an assistant
is
with
the
purif ication
blood
late
process
coagulation
monoclonal
which resulted
antibodies.
in
Theodore
f or
protein
blood
Zimmerman,
coaguJ-ation
used
to
treat
Ful-cher was honored for
the production
l.10RE
S.
of the
first
PAGE 2 --
DR.
CAROL A.
FULCHER AWARD
commercially
available,
which
hemophiliacs
of
all-ows
AIDS,
honored
VIII
hepatitis
for
her
molecule
inhibitor
options
and
work
and
to
be treated
other
on the
the
purified
viral
structure
concentrate
with
a greatly
j-nfections.
and
immunochemistry
of
VIII,
reduced
Fulcher
function
of
Factor
of
human
was
the
Factor
risk
also
Factor
VIIf
antibodies.
Fulcher
VIII,
highly
which
in
is
currently
could
both
Iead
hemophilia
researching
to
improved
the
diagnostic
A and thrombosis.
JI4JI
ttf
biochemistry
and
of
Factor
therapeutic